NYSE - Delayed Quote • USD
Perrigo Company plc (PRGO)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 6:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 5 | 5 |
| Avg. Estimate | 0.23 | 0.56 | 2.35 | 2.94 |
| Low Estimate | 0.23 | 0.5 | 1.49 | 1.78 |
| High Estimate | 0.23 | 0.6 | 2.6 | 3.28 |
| Year Ago EPS | 0.45 | 0.63 | 2.58 | 2.35 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 4 |
| Avg. Estimate | 1.09B | 1.18B | 4.66B | 4.86B |
| Low Estimate | 1.07B | 1.17B | 4.65B | 4.81B |
| High Estimate | 1.11B | 1.19B | 4.67B | 4.95B |
| Year Ago Sales | 1.18B | 1.19B | 4.66B | 4.66B |
| Sales Growth (year/est) | -7.50% | -1.20% | 0.10% | 4.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.42 | 0.5 | 0.62 | 0.83 |
| EPS Actual | 0.45 | 0.63 | 0.64 | 0.86 |
| Difference | 0.03 | 0.13 | 0.02 | 0.03 |
| Surprise % | 7.10% | 26.00% | 3.20% | 3.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.23 | 0.56 | 2.35 | 2.94 |
| 7 Days Ago | 0.23 | 0.56 | 2.35 | 2.94 |
| 30 Days Ago | 0.23 | 0.56 | 2.29 | 2.88 |
| 60 Days Ago | 0.7 | 0.75 | 2.99 | 3.41 |
| 90 Days Ago | 0.7 | 0.75 | 2.99 | 3.41 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | -- | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | 1 | -- | -- |
Growth Estimates
| CURRENCY IN USD | PRGO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -48.90% | -- | -- | 2.60% |
| Next Qtr. | -11.10% | -- | -- | 13.40% |
| Current Year | -8.90% | -- | -- | 5.20% |
| Next Year | 25.10% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 10.00% | -- | -- | 11.11% |
| Past 5 Years (per annum) | -13.46% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Canaccord Genuity: Buy to Buy | 4/12/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 4/8/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 2/28/2024 |
| Initiated | Piper Sandler: Overweight | 11/17/2023 |
| Maintains | JP Morgan: Overweight to Overweight | 8/9/2023 |
| Initiated | Canaccord Genuity: Buy | 3/7/2023 |
Related Tickers
TAK Takeda Pharmaceutical Company Limited
13.07
-1.21%
TEVA Teva Pharmaceutical Industries Limited
13.25
+1.84%
HLN Haleon plc
8.40
+0.60%
AMRX Amneal Pharmaceuticals, Inc.
5.90
-2.48%
VTRS Viatris Inc.
11.47
-0.69%
LFCR Lifecore Biomedical, Inc.
6.64
+4.90%
EBS Emergent BioSolutions Inc.
1.9500
-10.55%
INDV Indivior PLC
17.25
-8.29%
KMDA Kamada Ltd.
5.20
+0.39%
COLL Collegium Pharmaceutical, Inc.
35.84
+1.01%